Tesamorelin is FDA-approved with a well-characterized safety profile from Phase III trials. Common side effects include injection site reactions, arthralgia, and peripheral edema. It is contraindicated in active malignancy and pregnancy. It is a prescription medication requiring physician supervision.

Does tesamorelin work for fat loss in people without HIV?

The FDA-approved indication is for HIV-associated lipodystrophy. The same GH-mediated lipolytic mechanism is active in non-HIV populations, and off-label use is common. However, Phase III data specifically in non-HIV obesity or body composition optimization has not been published.

How is tesamorelin different from HGH?

Tesamorelin stimulates your pituitary gland to release growth hormone naturally, preserving pulsatile secretion patterns and feedback regulation. Exogenous HGH bypasses the pituitary entirely and delivers a flat, non-physiological dose. Tesamorelin produces GH levels within the physiologic range, while HGH can easily produce supraphysiological levels.

How does tesamorelin compare to sermorelin?

Both are GHRH analogs that stimulate pituitary GH release. Tesamorelin has current FDA approval with Phase III outcomes data showing visceral fat reduction. Sermorelin's approval was voluntarily withdrawn. Tesamorelin is considered more potent but is also more expensive. Both preserve physiologic pulsatile GH patterns.

What does the research show about: FDA-approved with Phase III outcomes data showing 15-18% visceral fat reduction ?

FDA-approved with Phase III outcomes data showing 15-18% visceral fat reduction in HIV-associated lipodystrophy. The only GHRH analog with current regulatory approval. This is what separates tesamorelin from sermorelin, CJC-1295, and ipamorelin: it demonstrated health outcomes in controlled trials, not just hormone elevation

What does the research show about: The GHRA trial demonstrated over 30% liver fat reduction in HIV patients with NA?

The GHRA trial demonstrated over 30% liver fat reduction in HIV patients with NAFLD over 12 months, with improvements in fibrosis markers. This liver fat data is from a controlled trial and represents one of the most promising non-approved applications

What does the research show about: RCT-demonstrated cognitive improvement in older adults (Stanley et al., 2015) wi?

RCT-demonstrated cognitive improvement in older adults (Stanley et al., 2015) with improvements in executive function and verbal memory. This is a single study requiring replication, but it is a genuine randomized controlled trial in a non-HIV population

What does the research show about: Preserves pulsatile GH release through the pituitary axis, producing more physio?

Preserves pulsatile GH release through the pituitary axis, producing more physiologic secretion patterns than exogenous GH injection. This physiological advantage reduces the risk of supraphysiological hormone levels and maintains natural feedback regulation

What does the research show about: FDA approval is narrow: HIV-associated lipodystrophy only. Efficacy in general o?

FDA approval is narrow: HIV-associated lipodystrophy only. Efficacy in general obesity, aging, or cognitive populations is not Phase III-validated. Off-label extrapolation is common but scientifically premature. Each new population needs its own confirmatory evidence

reviewed april 2026|next review october 2026|88 physicians psi has verified|110 published studies

Tesamorelin

Q: Is tesamorelin FDA-approved?

Yes. Tesamorelin is FDA-approved under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Off-label use for other indications has not been FDA-evaluated.

Tesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for the reduction of visceral abdominal fat in HIV-associated lipodystrophy. It is the only growth hormone-releasing hormone analog with current FDA approval.

Evidence landscape: 110 published studies

110 published items: 37 human studies and 44 animal studies. A focused clinical evidence base anchored by Phase III trials supporting the only FDA-approved GHRH analog.

37 Human
44 Animal
29 Reviews

FDA-approved prescription medicine in the United States as Egrifta (tesamorelin acetate) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Phase III trials in HIV lipodystrophy demonstrated 15-18% visceral fat reduction. Controlled trial data also exists for liver fat reduction and cognitive function in older adults.

The only peptide in the GHRH or GH secretagogue class with a current FDA-approved therapeutic indication. No other GHRH analog, GHRP, or growth hormone secretagogue holds this distinction.

PSI Assessment

Among all growth hormone secretagogues, only one has current FDA approval: tesamorelin, sold as Egrifta for the reduction of visceral fat in HIV-associated lipodystrophy. The Phase III trials demonstrated 15-18% visceral fat reduction, and it is the only compound in the GHRH class that has demonstrated body composition outcomes in controlled trials. The growing interest in tesamorelin for non-HIV body composition, liver fat reduction, and cognitive function, uses the FDA has not formally approved, is supported by early-phase data but not by the trials that earned the approval.

The only growth hormone secretagogue with current FDA approval. The only GHRH analog to demonstrate body composition outcomes in Phase III trials.

The mechanism is clean: tesamorelin is a 44-amino-acid analog of growth hormone-releasing hormone that stimulates the pituitary to release GH in a physiological pulsatile pattern. A trans-hexenoic acid modification at the N-terminus increases receptor binding and enzymatic stability. The resulting GH pulses drive lipolysis, particularly in visceral adipose tissue, and stimulate hepatic IGF-1 production. Unlike direct GH injection, tesamorelin preserves the feedback axis.

What the evidence supports

FDA-approved for visceral fat reduction in HIV-associated lipodystrophy. Phase III data demonstrates 15-18% trunk fat reduction. Liver fat reduction demonstrated in controlled trial. The only GHRH analog with current FDA approval and body composition outcomes data.

What is not yet established

Whether visceral fat reduction in HIV populations translates to non-HIV populations at the same magnitude. Whether cognitive improvements replicate beyond a single study. Long-term safety beyond 2 years of continuous use.

Research Evidence

The findings below cover what the Phase III program established and where the evidence thins for non-HIV applications.

Evidence by condition

Evidence dimensions across tesamorelin's approved and investigated indications. HIV lipodystrophy has the deepest evidence. Liver fat and cognitive function have controlled trial data but limited replication.

Condition	Mechanism	Animal evidence	Human evidence	Replication
HIV-Associated Lipodystrophy
Visceral Fat (Non-HIV)
Liver Fat Reduction (MASLD)
Cognitive Function
GH Stimulation

Phase III trials demonstrated 15-18% visceral fat reduction over 26 weeks in adults with HIV-associated lipodystrophy. Trunk fat decreased significantly versus placebo. These results are the basis for the FDA approval of Egrifta.

The effect is specific to visceral adipose tissue, with less impact on subcutaneous fat. Fat regain occurs after discontinuation, consistent with the chronic-treatment model.

A controlled trial in adults with HIV and NAFLD demonstrated more than 30% reduction in liver fat fraction over 12 months versus no change on placebo. The strongest controlled evidence for hepatic steatosis reduction in the GHRH class.

The population was HIV-associated NAFLD, not general MASH. Whether the liver fat reduction translates to non-HIV populations at the same magnitude is the key open question for this indication.

A randomized controlled trial in older adults reported executive function improvement after 20 weeks of tesamorelin treatment. The mechanism is hypothesized to involve IGF-1 signaling in the hippocampus.

Single study, not replicated. The cognitive signal is biologically plausible given IGF-1 receptor density in memory-relevant brain regions. A dedicated Phase III cognitive outcomes trial has not been conducted.

37 Human|44 Animal|29 Reviews

View all 110 indexed studies

How Tesamorelin Works

Tesamorelin is a 44-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) with a trans-hexenoic acid modification for improved stability. It is the only GHRH analog with current FDA approval.

Tesamorelin works by sending a signal to your pituitary gland to release growth hormone naturally. Unlike injecting growth hormone directly (which bypasses your body's control system), tesamorelin preserves the normal on/off switches. The increased growth hormone then drives fat breakdown, particularly in deep belly fat. It is the proof of concept that GHRH-based peptides can produce real body composition outcomes in humans.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, activating adenylyl cyclase via Gs-protein coupling, which increases intracellular cAMP and stimulates pulsatile GH gene transcription and secretion. The trans-3-hexenoic acid modification at the N-terminus increases GHRH receptor binding affinity and enzymatic stability compared to native GHRH. The resulting GH pulses drive hepatic IGF-1 production and stimulate lipolysis, particularly in visceral adipose tissue through differential hormone-sensitive lipase activation. Unlike exogenous GH, tesamorelin maintains the hypothalamic-pituitary feedback axis.

What is Tesamorelin being studied for?

Researchers are studying Tesamorelin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Tesamorelin overall. This means a compound can have human studies for one condition but only animal data for another.

HIV-Associated Lipodystrophy

·FDA Approved

Phase III trials demonstrated visceral adipose tissue reduction of 15-18% over 26 weeks. FDA-approved as Egrifta for this indication.

Limitations: Approved population is specific (HIV patients on antiretroviral therapy with lipodystrophy). Fat regain occurs after discontinuation. Generalization to non-HIV populations requires separate confirmation.

Visceral Fat (Non-HIV)

·Human Trials

Mechanistic rationale and some clinical data support visceral fat reduction in non-HIV populations. The approved dose and protocol are extrapolated from the HIV program.

Limitations: No Phase III trial has been conducted in a non-HIV visceral fat population. Use outside the approved indication is extensive but controlled confirmation is pending.

Liver Fat Reduction (MASLD)

·Human Trials

A randomized controlled trial demonstrated more than 30% reduction in liver fat fraction in adults with HIV and NAFLD over 12 months.

Limitations: Single trial in an HIV population. Phase III in general MASLD not conducted.

Cognitive Function

·Animal Studies

A randomized controlled trial in older adults reported executive function improvement over 20 weeks. The mechanism involves IGF-1 signaling in brain regions relevant to memory.

Limitations: Single study. Not replicated. No dedicated Phase III cognitive outcomes trial conducted.

GH Stimulation

·FDA Approved

Tesamorelin reliably stimulates pituitary GH release in a dose-dependent pulsatile pattern. This is the pharmacological basis for the FDA-approved indication.

Limitations: GH stimulation is the mechanism, not a clinical endpoint. The clinical value depends on what downstream outcomes the GH increase produces.

Safety and Regulatory Status

FDA Status: FDA-approved as Egrifta (tesamorelin acetate) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Prescription status: Prescription-only in the United States. Available through specialty and retail pharmacies.

Class context: The only GHRH analog with current FDA approval. Other compounds in the class (sermorelin, CJC-1295) are available only through specialty pharmacies, where a licensed pharmacist prepares a medicine from ingredients for an individual patient, or are investigational.

Common side effects include injection-site reactions, joint pain, and peripheral edema. Fluid retention and paresthesias are consistent with the GH-raising mechanism. Tesamorelin is contraindicated in patients with active malignancy or disruption of the hypothalamic-pituitary axis.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a Tesamorelin discussion.

Comparison and Related Research

Tesamorelin is most often compared with other growth hormone secretagogues and GHRH analogs. The comparisons below outline how each differs in regulatory status, evidence depth, and mechanism.

Head-to-head comparisons

Full research comparisons covering Tesamorelin and another peptide side by side.

Tesamorelin vs CJC-1295

Tesamorelin is FDA-approved for HIV lipodystrophy. CJC-1295 is a research compound used broadly. Same receptor, different regulatory status. Evidence compared.

View full comparison

Tesamorelin vs MK-677

Tesamorelin is FDA-approved for lipodystrophy. MK-677 is oral with more general GH data. Evidence-graded comparison.

View full comparison

Related compounds

Sermorelin CJC-1295 Ipamorelin MK-677

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Phase III trial in 412 adults with HIV-associated abdominal fat accumulation over 26 weeks. Visceral adipose tissue reduction of 15.2% at the 2 mg dose versus 5% gain on placebo. Basis for the FDA approval.Falutz J et al., 2007 in N Engl J Med. View on PubMed
2.Follow-up analysis linking visceral fat reduction with improved triglycerides and adiponectin. Demonstrated metabolic benefit beyond the primary body composition endpoint.Stanley TL et al., 2014 in JAMA. View on PubMed
3.Randomized placebo-controlled trial in 61 adults with HIV and NAFLD over 12 months. Liver fat fraction reduced more than 30% from baseline versus no change on placebo. The strongest controlled evidence for hepatic outcomes in the class.Stanley TL et al., 2019 in Lancet HIV. View on PubMed
4.Randomized controlled trial using the same compound in older adults with and without mild cognitive impairment. Executive function improvement across 20 weeks of treatment. Single study, not yet replicated.Baker LD et al., 2012 in Arch Neurol. View on PubMed
5.52-week extension study. Effects on visceral fat sustained with continued treatment and reversed after discontinuation. Favorable long-term safety profile.Falutz J et al., 2010 in J Clin Endocrinol Metab. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.